Oncology

A new drug candidate demonstrated the potential to control inflammation for cancer patients in findings that were recently announced in Proceedings of the National Academy of Sciences.

In a study conducted, antidepressants slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they stopped cancer growth long-term.

IDP-126, an acne vulgaris treatment for patients ages 9 and older, met all of its endpoints in a 12-week phase 3 study.

Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.

An expert highlights the progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.

The consumer products giant voluntarily recalled 4 NEUTROGENA® and 1 AVEENO® spray sunscreen products July 14 after internal testing found low levels of benzene, a carcinogen, in some product samples.

A study from the 2021 ASCO Annual Meeting examined the effect that oral anticancer agent initiation may have on adherence rates in patients with multiple myeloma and chronic conditions.

A study from the 2021 ASCO Annual Meeting assessed the prevalence of oncology drug shortages and how they hinder care for patients with cancer.

A poster presentation at the 2021 ASCO Annual Meeting discussed survival trends among patients with chronic lymphocytic leukemia.

A community oncology practice implemented a team-based approach to utilizing biosimilars.

Results of the phase 3 OlympiA study evaluating olaparib as adjuvant therapy in high-risk early-stage breast cancer therapy were presented at the 2021 ASCO Annual Meeting.

A study highlighted at the 2021 ASCO Annual Meeting explored whether patients who received an influenza vaccine were at increased risk for immune-related adverse events from single-agent immune checkpoint inhibitors.

Results of the phase 3 RATIONALE 203 study were presented at the 2021 ASCO Annual Meeting.

Findings from the phase 3 RELATIVITY-047 trial were presented at the 2021 ASCO Annual Meeting.

The FDA has approved sotorasib (Lumakras; Amgen Inc) for the treatment of non-small cell lung cancer in patients with KRAS G12C genetic mutations and who have received at least 1 prior therapy.

A session from the 2021 PQA Annual Meeting highlighted the benefits of virtual outreach in advancing patient care amid the COVID-19 pandemic and beyond.

Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.

The future of clinical trials in a post pandemic world will rely on a patient-centered approach. Pharmacists can play a role to caring for these patients.

A session held at the HOPA Annual Meeting 2021 discussed investigational cancer drugs in clinical trials.

A session held at the HOPA Annual Meeting 2021 discussed best practices for optimizing opioid treatment in patients with cancer pain.

This indication is approved under accelerated approval based on tumor response rate and durability of response.

Research presented at the HOPA Annual Conference 2021 supported the benefit and feasibility of a pharmacy-led adherence and monitoring program for oral antineoplastic agents.

Findings presented at the Hematology/Oncology Pharmacists Association Annual Meeting 2021 discussed burnout and job dissatisfaction among oncology and hematology pharmacists.

At the HOPA Annual Conference 2021, Lakesha Butler, PharmD, BCCPS, discussed how pharmacists can disrupt the status quo to fight racism and work toward health equity for all.

Oncology programs provide the tools needed to improve patient outcomes.

Clinical trial data showed that the isatuximab (Sarclisa; Sanofi) regimen reduced risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

The approval of the first-line treatment was granted to Regeneron Pharmaceuticals.

Alliance will provide insight, education, and training opportunities to pharmaceutical and life sciences professionals.

The market for acute lymphocytic leukemia and bladder cancer drug therapies is expected to soar over the next few years, thanks in part to new and innovative medications.

A new online tool allowing AllianceRx Walgreens Prime oncology patients to refill their own prescriptions saves time, while still providing pharmacists’ help when needed.